|  |
| --- |
| Table E4. SD-OCT measurement (µm) of RNFL and BMO-MRW thickness in the three Groups (NAION, Unaffected Fellow Eyes, and healthy controls)  |
|  | NAION eyes(N=29) | Contralateral unaffected eyes(N=21) | Control eyes(N=29) | NAION vs contralateral unaffected | NAION vs controls | Contralateral unaffected vs controls | P ANOVA |
| *RNFL-GMP, m* |  |
| Superotemporal | 61.72±21.99 | 132.28±15.41 | 129.96±16.74 | 0.00 | 0.00 | 0.62 | 0.00 |
| Superonasal | 48.75±16.92 | 105.95±26.32 | 105.10±21.21 | 0.00 | 0.00 | 0.90 | 0.00 |
| Nasal | 43.27±19.01 | 76.90±15.32 | 74.82±11.73 | 0.00 | 0.00 | 0.59 | 0.00 |
| Inferionasal  | 76.55±33.73 | 123.23±21.10 | 105.89±26.64 | 0.00 | 0.00 | 0.01 | 0.00 |
| Inferotemporal | 94.34±44.19 | 147.04±10.84 | 135.89±16.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Temporal | 40.93±11.72 | 70.61±8.89 | 68.11±10.28 | 0.00 | 0.00 | 0.37 | 0.00 |
| Average | 56.17±15.30 | 99.95±7.79 | 95.82±8.78 | 0.00 | 0.00 | 0.09 | 0.00 |
| *BMO-MRW,m* |  |
| Superotemporal | 230.82±75.68 | 367.52±72.57 | 307.14±60.64 | 0.00 | 0.00 | 0.00 | 0.00 |
| Superonasal | 290.07±84.85 | 433.95±76.73 | 366.55±67.68 | 0.00 | 0.00 | 0.00 | 0.00 |
| Nasal | 294±14.77.67 | 404.47±57.46 | 373.85±65.00 | 0.00 | 0.00 | 0.09\* | 0.00 |
| Inferionasal  | 339.53±74.07 | 443.42±60.50 | 397.18±70.43 | 0.00 | 0.00 | 0.02 | 0.00 |
| Inferotemporal | 279.35±63.21 | 372.85±54.88 | 335.96±55.86 | 0.00 | 0.00 | 0.02 | 0.00 |
| Temporal | 187.85±55.80 | 271.09±51.05 | 229.40±50.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average | 264.14±57.46 | 370.66±52.70 | 327.92±52.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Data are presented as mean±SD.; BMO-MRW, Bruch membrane opening-minimum rim width. NAION, non-arteritic ischaemic optic neuropathy; pCT, peripapillary choroidal thickness.  |